Equecabtagene Autoleucel
IASO Biotherapeutics
['multiple myeloma', 'iaso bio', 'innovent']
innovent and iaso bio updated efficacy and safety clinical data of equecabtagene autoleucel (bcma car-t cell therapy) for multiple myeloma at the 2023 asco annual meeting 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.